The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials

Authors

  • Dat T Tran School of Public Health, University of Alberta, Edmonton, Alberta, Canada
  • Ilke Akpinar Institute of Health Economics, Edmonton, Alberta, Canada
  • Richard Fedorak Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
  • Egon Jonsson Institute of Health Economics, Edmonton, Alberta, Canada
  • John Mackey Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
  • Lawrence Richer Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
  • Philip Jacobs Institute of Health Economics, and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

DOI:

https://doi.org/10.18433/J3DH0V

Abstract

Purpose: In pharmaceutical clinical trials, industrial sponsors pay for study drugs and related healthcare services. We conducted a study to determine industry’s economic contribution of these trials to the Alberta healthcare system. 
Methods: We used data from two trial centers for cancer and non-cancer trials at the University of Alberta. For each trial (cancer, non-cancer), we calculated the cost of drugs provided by the sponsors using the market price, the cost of clinical services, and the cost of administrative services that they paid. We extrapolated these results to all trials in Alberta based on information obtained from the registration website ClinicalTrials.gov. 
Results: Our sample consisted of 40 non-cancer and 39 cancer drug trials which were initiated in 2012. The monetary value of the industry sponsors’ contribution was $799,055 per non-cancer and $630,243 per cancer drug trial. Drugs (in-trial and post-trial) accounted for 84% of the total contribution of the non-cancer drug trials whereas it represented 93% of all trial-related contributions in the cancer category. The total province-wide contribution of industry-sponsored drug trials which were initiated in 2012 was estimated to be $101 million, including open-label drugs in the non-cancer category. 
Conclusions: Industry-sponsored pharmaceutical trials represent a major economic contributor to clinical research within the province.

Downloads

Download data is not yet available.

Downloads

Published

2018-01-09

How to Cite

Tran, D. T., Akpinar, I., Fedorak, R., Jonsson, E., Mackey, J., Richer, L., & Jacobs, P. (2018). The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials. Journal of Pharmacy & Pharmaceutical Sciences, 20(1), 407–414. https://doi.org/10.18433/J3DH0V

Issue

Vol. 20 (2017): Pages 319-452

Section

Pharmaceutical Sciences; Original Research Articles

License

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.